<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01882296</url>
  </required_header>
  <id_info>
    <org_study_id>AGSPT_PD</org_study_id>
    <nct_id>NCT01882296</nct_id>
  </id_info>
  <brief_title>Investigate a Pharmacodynamics Between S-pantoprazole 10, 20, 40mg and Pantoprazole 20, 40mg in Healthy Male Subjects</brief_title>
  <acronym>AGSPT_PD</acronym>
  <official_title>A Block-randomized, Open-Label, Multiple Oral Dosing, Phase I Study to Explore Comparability of the Pharmacodynamics Between S-pantoprazole 10, 20, 40mg and Pantoprazole 20, 40mg in Healthy Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ahn-Gook Pharmaceuticals Co.,Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ahn-Gook Pharmaceuticals Co.,Ltd</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary object: Evaluate Pharmacodynamic property and safety administered S-pantoprazole 10,
      20, 40mg and Pantoprazole 20, 40mg in healthy male subjects

      Secondary object : Evaluate Dose-response of S-pantoprazole and pantoprazole and compare each
      dose-response
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <primary_completion_date type="Anticipated">September 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>24h pH</measure>
    <time_frame>24 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>%Time pH&gt;6</measure>
    <time_frame>24 hours</time_frame>
    <description>(Time(hour) percent when pH &gt;6) / 24(hours)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>% inhibition time gastric pH≤4</measure>
    <time_frame>24 hours</time_frame>
    <description>100-(percent time pH &gt;4)</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Healthy Male Subjects</condition>
  <arm_group>
    <arm_group_label>AGSPT_10</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>tablet, 10mg, QD, 7days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AGSPT_20</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>tablet, 20mg, QD, 7days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AGSPT_40</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>tablet, 20mg x 2, QD, 7days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pantoprazole_20</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>tablet, 20mg, QD, 7days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pantoprazole_40</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>tablet, 40mg, QD, 7days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AGSPT_10</intervention_name>
    <description>AGSPT 10mg for 7days administration</description>
    <arm_group_label>AGSPT_10</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AGSPT_20</intervention_name>
    <description>AGSPT 20mg for 7days administration</description>
    <arm_group_label>AGSPT_20</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AGSPT_40</intervention_name>
    <description>AGSPT 20mg x 2tablet for 7days administration</description>
    <arm_group_label>AGSPT_40</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pantoprazole_20</intervention_name>
    <description>Pantoprazole 20mg for 7days administration</description>
    <arm_group_label>Pantoprazole_20</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pantoprazole_40</intervention_name>
    <description>Pantoprazole 40mg for 7days administration</description>
    <arm_group_label>Pantoprazole_40</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult healthy males 20 to 45 years at screening

          -  BMI : 19kg/m2 ~ 26 kg/m2

          -  Blood Pressure : &quot;140 mmHg ≥ sitting SBP ≥ 90 mmHg, 95 mmHg ≥ sitting DBP ≥ 50 mmHg&quot;

        Exclusion Criteria:

          -  Have history of significant hepatic, renal gastrointestinal, pulmonary,
             musculoskeletal, endocrine, neuropsychiatric, hematologic, cardiovascular diseases

          -  Have a gastrointestinal disease(ex : Crohn's disease, gastrointestinal ulcer) or
             surgery (except for Appendectomy, hernia repair) affected the absorption of
             medications

          -  Have history of GERD, Gastric ulcer, Duodenal ulcer and H.pylori positive

          -  Hypersensitivity reactions to drugs of clinically significant hypersensitivity
             reactions in the history of benzimidazole (ex: pantoprazole, NSAID, antibiotic)

          -  Have a history of drug abuse

          -  unusual diet affected the absorption, distribution, metabolism, excretion of
             medications

          -  Subject who treated with any investigational drugs within 90 days before the
             administration of investigational drug

          -  Subject who takes inhibitors and inducers of drug metabolizing enzyme (Barbiturates
             etc.) within 30days

          -  Previously donate whole blood within 60 days or component blood within 30 days or
             transfusion within 30 days

          -  Subject who have taken habitually caffeine (caffeine &gt; 5 units/day)

          -  Subject who have drunken habitually (alcohol &gt; 21 units/week, 1 unit = pure alcohol
             10ml)or who are unable to quit drinking during this study or smoker

          -  Subjects deemed ineligible by investigator based on other reasons
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>May 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 18, 2013</study_first_submitted>
  <study_first_submitted_qc>June 19, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 20, 2013</study_first_posted>
  <last_update_submitted>June 19, 2013</last_update_submitted>
  <last_update_submitted_qc>June 19, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 20, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pantoprazole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

